Cost-benefit analysis of endocrine therapy in the adjuvant setting for postmenopausal patients with hormone receptor-positive breast cancer, based on survival data and future prices for generic drugs in the context of the German health care system

Breast Care

Volumn 6, Issue 5, 2011, Pages 381-389

  Lux, Michael P ^a   Reichelt, Claudia ^b   Karnon, Jon ^c   Tänzer, Thorsten D ^d   Radosavac, Dragan ^e   Fasching, Peter A ^a   Beckmann, Matthias W ^a   Thiel, Falk C ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Pharmacoeconomy   (Germany)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d Medicornea Ltd   (Germany)

^e Krankenhaus Bethanien   (Germany)

Author keywords

Anastrozole; ATAC; BIG 1 98; Cost effectiveness; Letrozole; QALY; Tamoxifen

Indexed keywords

ANASTROZOLE; GENERIC DRUG; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; GERMANY; HEALTH CARE SYSTEM; HORMONAL THERAPY; HUMAN; HUMAN EXPERIMENT; MENOPAUSAL SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK;

EID: 84655166232     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000333118     Document Type: Article

References (38)

1. Porzsolt F: Klinische Ökonomik. Die ökonomische Bewertung von Gesundheitsleistungen aus der Sicht des Patienten; in Porzsolt F, Williams AR, Kaplan RM (eds): Klinische Ökonomik. Effektivität und Effizienz von Gesundheitsleistungen. Landsberg, ecomed, 2003, pp 17-40.
2. Lux MP, Beckmann MW: Klinische Ökonomie in der gynäkologischen Onkologie. Frauenheilkd Akt 2008;2:35-41.
3. Bundesministerium für Gesundheit: www.bmg.bund.de/ krankenversicherung/arzneimittelversorgung/amnog.html, 2011.
4. Bundesministerium für Gesundheit: Gesetz zur Neuordnung des Arzneimittelmarktes (AMNOG). www.bmg.bund.de/krankenversicherung/ arzneimittelversorgung/amnog/amnog.html, 2010.
5. Robert Koch-Institut: Verbreitung von Krebserkrankungen in Deutschland. Entwicklung der Prävalenzen zwischen 1990 und 2010. Beiträge zur Gesundheitsberichterstattung des Bundes. Berlin, Westkreuz-Druckerei, 2010, pp 77-82.
6. Brown SB, Mallon EA, Edwards J, Campbell FM, McGlynn LM, Elsberger B, Cooke TG: Is the biology of breast cancer changing? A study of hormone receptor status 1984-1986 and 1996-1997. Br J Cancer 2009;100:807-810.
7. [No authors listed]: Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467.
8. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; Breast International Group (BIG) 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757. (Pubitemid 43016814)
9. Mouridsen HT, Giobbie-Hurder A, Mauriac L, Paridaens R, Colleoni M, Thuerlimann B, Forbes JF, Gelber RD, Wardley A, Goldhirsch A; BIG 1-98 Collaborative Group and International Breast Cancer Study Group (IBCSG), Bern, Switzerland: BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Cancer Res 2009;69(suppl):abstr 13.
10. Regan MM, Colleoni M, Giobbie-Hurder A, Thuerlimann B, Mouridsen H, Mauriac L, Paridaens R, Forbes JF, Wardley A, Smith I, Price KN, Goldhirsch A, Coates AS, Gelber RD: BIG 1-98 Collaborative and International Breast Cancer Study groups. Adjusting for selective crossover in analyses of letrozole (Let) versus tamoxifen (Tam) in the BIG 1-98 Trial. Cancer Res 2009;69(suppl):488s- 489s.
11. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
12. Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-338. (Pubitemid 24013155)
13. Institut für Qualität und Wissenschaftlichkeit im Gesundheitswesen: Methods for assessment of the relation of benefits to costs in the German statutory health care system. Version 1.1. http://iqwig.de/index. 805.en.html, 2008.
14. Kassenärztliche Vereinigung Bayerns: Bayerische Euro- Gebührenordnung und EBM-Änderungen ab 1. April 2010. www.kvb.de, 2010.
15. Deutsche Krebsgesellschaft; Kreienberg R, Kopp I, Albert U, Bartsch HH, Beckmann MW, Berg D, Bick U, du Bois A, Budach W, Dunst J, Engel J, Ernst B, Geraedts M, Henscher U, Hölzel D, Jackisch C, König K, Kreipe H, Kühn T, Lebeau A, Leinung S, Link H, Lück HJ, Madjar H, Maiwald A, Maiwald G, Marschner N, Marx M, von Minckwitz G, Nass-Griegoleit I, Possinger K, Reiter A, Sauerbrei W, Schlake W, Schmutzler R, Schreer I, Schulte H, Schulz KD, Souchon R, Thomssen C, Untch M, Wagner U, Weis J, Zemmler T: Interdisziplinäre S3-Leitlinie - Diagnostik, Therapie und Nachsorge beim Mammakarzinom. Munich, Zuckschwerdt Verlag, 2008.
16. Rote Liste: Rote Liste® Service GmbH 2010. www.rote-liste.de, info@rote-liste.de.
17. Lux MP, Graf C, Hildebrandt T, Bani MR, Löhberg CR, Schrauder MG, Thiel FC, Fasching PA, Beckmann MW: Health Utilities in der Gynäkologischen Onkologie und Senologie in Deutschland. Onkologie 2010;33(suppl 2):191.
18. Sorensen S, Brown R, Benedict A: Patient-rated utilities in postmenopausal early breast cancer: a cross country comparison. Value Health 2004;7: 637-657.
19. Lux MP, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann MW, Thiel FC: Results of the Zometa cost-utility model for the German healthcare system based on the results of the ABCSG-12 study. Onkologie 2010;33:360-368.
20. Wagner S, Bani MR, Fasching PA, Schrauder MG, Löhberg CR, Beckmann MW, Lux MP: Ist ein Brustzentrum finanzierbar? - Berechnung einzelner Leistungen am Beispiel des Universitäts-Brustzentrums Franken (UBF). Geburtshilfe Frauenheilkd 2008;68:1178-1183.
21. Lux MP, Hartmann M, Jackisch C, Raab G, Schneeweiss A, Possinger K, Oyee J, Harbeck N: Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model. Breast Cancer Res Treat 2009;117:305-317.
22. Dodel RC, Haacke C, Zamzow K, Paweilik S, Spottke A, Rethfeldt M, Siebert U, Oertel WH, Schöffski O, Back T: Resource utilization and costs of stroke unit care in Germany. Value Health 2004;7:144-152. (Pubitemid 38420727)
23. 3M Suite. http://solutions.3mdeutschland.de/wps/portal/3M/de-DE/his/drg/ product-information/coding-grouping/3msuite, 2010.
24. Topaloglu O, Unalp A: Review of cost-effectiveness studies on aromatase inhibitors for the treatment of early-stage breast cancer. J Clin Oncol 2010;28(suppl 15):abstr e11030.
25. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L: Hormonal therapies for early breast cancer: a systematic review and economic evaluation. Health Technol Assess 2007;11:iii-iv, ix-xi, 1-134.
26. Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V: Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 2007;7:608-618. (Pubitemid 47025818)
27. Delea TE, El-Ouagari K, Karnon J, Sofrygin O: Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat 2008;108:375-387. (Pubitemid 351431071)
28. Mansel R, Locker G, Fallowfield L, Benedict A, Jones D: Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Br J Cancer 2007;97:152-161. (Pubitemid 47057463)
29. Karnon J, Delea T, Barghout V: Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ 2008;9:171-183. (Pubitemid 351535306)
30. Hillner BE: Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 2004;101:1311-1322. (Pubitemid 39180386)
31. Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, Gandhi SK; ATAC Trialists' Group: Cost-effectiveness analysis of anastrazole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 2007;106:229-238. (Pubitemid 350045007)
32. Karnon J: Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer. Expert Rev Pharmacoecon Outcomes Res 2007;7:143-153. (Pubitemid 46690968)
33. Skedgel C, Rayson D, Dewar R, Younis T: Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifenletrozole. Breast 2007;16:252-261. (Pubitemid 46796849)
34. Lux MP, Wöckel A, Benedict A, Buchholz S, Harbeck N, Kreienberg R, Kaufmann M, Beckmann MW, Jonat W, Hadji P, Distler W, Raab G, Tesch H, Weyers G, Possinger K, Schneeweiss A: Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. Onkologie 2010;33:155-166.
35. Cuzick J: Primary endpoints for randomised trials of cancer therapy. Lancet 2008;371:2156-2158. (Pubitemid 351885027)
36. Seruga B, Tannock IF: Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol 2009;27:840-842.
37. Karnon J, Kaura S: Updated survival-based analysis using inverse probability of censoring weighted analysis (IPCW) to estimate the cost-effectiveness of letrozole and anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer. J Clin Oncol 2010;28(suppl 15):abstr 656.
38. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI: Early discontinuation and nonadherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126: 529-537.